BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

640 related articles for article (PubMed ID: 26399658)

  • 1. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
    Kidger AM; Sipthorp J; Cook SJ
    Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms.
    Wu PK; Park JI
    Semin Oncol; 2015 Dec; 42(6):849-62. PubMed ID: 26615130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
    Little AS; Balmanno K; Sale MJ; Newman S; Dry JR; Hampson M; Edwards PA; Smith PD; Cook SJ
    Sci Signal; 2011 Mar; 4(166):ra17. PubMed ID: 21447798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
    Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
    Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of MEK inhibitors.
    Zhao Y; Adjei AA
    Nat Rev Clin Oncol; 2014 Jul; 11(7):385-400. PubMed ID: 24840079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
    Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
    Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
    Mandal R; Becker S; Strebhardt K
    Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.
    Sale MJ; Cook SJ
    Biochem Soc Trans; 2014 Aug; 42(4):776-83. PubMed ID: 25109957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer.
    Wang C; Wang H; Zheng C; Liu Z; Gao X; Xu F; Niu Y; Zhang L; Xu P
    Eur J Med Chem; 2021 Jun; 218():113386. PubMed ID: 33774345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
    Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
    BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
    Miller CR; Oliver KE; Farley JH
    Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology and clinical development of MEK inhibitors for cancer.
    Luke JJ; Ott PA; Shapiro GI
    Drugs; 2014 Dec; 74(18):2111-28. PubMed ID: 25414119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy.
    Frémin C; Meloche S
    J Hematol Oncol; 2010 Feb; 3():8. PubMed ID: 20149254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK2 controls the activation of MKK3/MKK6-p38 axis involved in the MDA-MB-231 breast cancer cell survival: Correlation with cyclin D1 expression.
    Huth HW; Albarnaz JD; Torres AA; Bonjardim CA; Ropert C
    Cell Signal; 2016 Sep; 28(9):1283-1291. PubMed ID: 27181679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.
    Little AS; Balmanno K; Sale MJ; Smith PD; Cook SJ
    Biochem Soc Trans; 2012 Feb; 40(1):73-8. PubMed ID: 22260668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.